Targeted therapeutics
AssigneeMadrigal Pharmaceuticals, Inc.
InventorsNeera Jain, Weiwen Ying, Dinesh U. Chimmanamada, Junyi Zhang, Amit Kale
Life of this patent
Estimating the term…
Abstract
The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
Claims1
A process of producing SDC-TRAP-0063 Sodium
- or its tautomer comprising the steps of:
- 1). dissolving SDC-TRAP-0063 in tert-butanol at 25-35° C.;
- 2). adding 0.3 normal aqueous sodium hydroxide and Water for Injection to adjust pH to be above around 9.8;
- 3). filtering the mixture from step 2). with at least two 0.2 μm filters in series;
- and
- 4). conducting aseptic vial filling and lyophilization.
Dependencies are inferred from the claim text.